Melodiol Global Health Limited

Quarterly Activities Report: Record Revenues for Melodiol

Melodiol Global Health Limited (ASX:ME1, FRA:1X8) (‘Melodiol’ or ‘the Company’) is pleased to provide the following report on progress for the three month period ended 30 June 2023 (the ‘quarter’), which is accompanied by the Company’s Appendix 4C. All financial results are in Australian dollars (unless otherwise stated) and unaudited.


Highlights:

  • Unaudited net sales for the combined Melodiol group of $4.74m – 105% gain on last quarter and a 202% increase on the PCP
  • Q2 sales take H1 CY23 net sales to $7.06m – a 64% uplift on H1 CY22 (H1 CY22:$4.31m)
  • Acquisition of Health House International (HHI) completed - HHI generated combined currency-adjusted unaudited revenues of $11.04m with an unaudited adjusted EBITDA margin in operating units for the period of 7.4% from January 2023 to 30 June 2023
  • Net cash used in operating activities totalled $2,378,000 - improved significantly on the last quarter by 43%
  • Mernova continued to pursue multiple growth initiatives, including ongoing expansion of its Canadian footprint and EU GMP licencing to fast track international cannabis exports
  • Letter of Intent (LOI) secured to enter an exclusive commercial relationship with Apotheke Dr. Hysek AG, a leading Swiss pharmaceutical company, for the supply of GMP MDMA and synthetic psilocybin products to the Australian market
  • Through its wholly owned Australian subsidiary HHI, Melodiol holds the necessary import licences for the Australian market and will provide the support infrastructure to import, warehouse and distribute the products throughout Australia – additional import permits to be pursued shortly
  • Promising early results from Halucenex’s Phase II clinical trial to test the efficacy of psilocybin on treatment-resistant Post Traumatic Stress Disorder (PTSD) with first 10% of trial patients experiencing total remission from depression and PTSD symptoms after the first macro-dose

Management commentary:

Chief Executive Officer Mr William Lay said: “Melodiol has delivered another quarter of strong revenue growth, as well as a considerable reduction in net cash used in operating activities. These financial results reiterate the Company’s ongoing strategy and validate the recent optimisation initiatives undertaken across the business.

“We anticipate revenue growth to continue over the near term as we continue to streamline our operating divisions and continue to implement Health House International into the broader Melodiol group.

“The acquisition of HHI has provided Melodiol with a number of key opportunities, particularly around the Australian and European markets which can be leveraged to unlock significant value for shareholders over the coming months. I look forward to providing additional updates over the coming months.”

Financial and corporate overview:

Financial performance:

For the June quarter, Melodiol reported preliminary net sales of A$4.74m, up 105% from the previous quarter (A$2.32m) and 202% higher than the prior year comparative period (A$1.57m). This takes unaudited sales for the first half of CY23 to $7.05m, which marks a 64% uplift on H1 CY22 (A$4.31m).

In addition, Melodiol continued to focus on a program to reduce operating costs without affecting growth. Net cash used in operating activities totalled $2,378,000, which predominately encompassed product and manufacturing, staff costs and administrative expenses. Pleasingly, net cash used in operating activities reduced significantly on the last quarter by 43%. The Company will continue to maintain its focus on cost control over the coming quarters.

At quarter end, Melodiol had cash at bank of $1,057,000. Payments to related parties and their associates as detailed in section six of the Appendix 4C relate to Directors Fees ($263,000), Loan repayment ($1,000) and other services ($145,000).

Completion of Health House International Limited acquisition:

Melodiol completed the acquisition of Health House International Limited (“Health House” or “HHI”) during the quarter. Completion of the acquisition followed approval from the Supreme Court of Western Australia, which made orders on 4 May 2023 approving the scheme of arrangement pursuant to which Melodiol acquired 100% of the shares in Health House.


Click here for the full ASX Release

This article includes content from Melodial Global Health, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

Melodiol Global Health

Melodiol Global Health Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Melodiol Global Health

Melodiol Global Health


Keep reading...Show less

Trulieve to Open Medical Cannabis Dispensary in Pinellas Park, Florida

New Pinellas County location will host grand opening celebration Saturday

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced the opening of a new medical cannabis dispensary in Pinellas Park, Florida .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
cannabis leaves, ukraine flag

Cannabis Round-Up: Ukraine Legalizes Medical Cannabis, Blüm to Acquire California Stores

Cannabis company Blüm Holdings (OTCQB:BLMH) signed a letter of intent to purchase three California retail locations from Operators Only this week in a bid to expand its business into Sacramento.

Meanwhile, Ukraine passed legislation to legalize medical cannabis use, and Québec's only cannabis retailer reported its results for the third quarter of 2023, showing sales growth. Also, after years of trying to establish an adult-use cannabis market, Virginia's Senate and the House of Delegates approved two separate cannabis sales bills.

Stay up to date on the latest news, trends and policy developments in the cannabis industry with our round-up below.

Keep reading...Show less

Cronos Group Inc. to Hold 2023 Fourth Quarter and Full-Year Earnings Conference Call on February 29, 2024

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company") will hold its 2023 fourth quarter and full-year earnings conference call on Thursday, February 29, 2024 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks.

To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations . To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on the Company's website.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Trulieve Cannabis Corp. to Hold Fourth Quarter and Full Year 2023 Results Conference Call on February 29, 2024

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., will hold a conference call on Thursday, February 29, 2024 at 8:30 AM Eastern Time following the release of its fourth quarter and full year 2023 financial results.

Trulieve logo (PRNewsfoto/Trulieve Cannabis Corp.)

Chairman, Founder, and Chief Executive Officer Kim Rivers and Chief Financial Officer Wes Getman will participate on the call to review Trulieve's financial and operating results.

Interested parties can join the conference call by dialing in as directed below. Please dial in 15 minutes prior to the call and ask to join the Trulieve Cannabis Corp. call.






North American toll free: 1-844-824-3830

Passcode:

1674609


International: 1-412-542-4136

Passcode:

1674609





A live audio webcast of the conference call will be available at:
https://app.webinar.net/rGl0B9nPzjZ

An archived replay of the webcast will be available at:
https://investors.trulieve.com/events

About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com .

Facebook: @Trulieve
Instagram: @Trulieve _
X: @Trulieve

Investor Contact
Christine Hersey , Vice President of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

Media Contact
Phil Buck , APR, Corporate Communications Manager
+1 (406) 370-6226
Philip.Buck@Trulieve.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-cannabis-corp-to-hold-fourth-quarter-and-full-year-2023-results-conference-call-on-february-29-2024-302052287.html

SOURCE Trulieve Cannabis Corp.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2024/05/c5649.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
cannabis leaves, american flag

Cannabis Round-Up: Texas Attorney General Sues Local Cities for Decriminalization Efforts

Texas' attorney general is suing five states for enacting local decriminalization measures.

Meanwhile, Kentucky has introduced a second bill to legalize cannabis, this time with measures that allow for a recreational market, and Florida has passed a bill that would place THC limits on recreational cannabis.

Keep reading for a round-up of this week's top news and trends in the cannabis industry.

Keep reading...Show less
australian dollar bills with jar of cannabis flower on table

Top 3 ASX Cannabis Stocks

Australia's cannabis industry is complex, with varying regulations across different states and territories.

While medical cannabis is legal at the federal level, recreational use is still prohibited in most parts of the country, with the only exception being the Australian Capital Territory — and even it has no dispensaries to legally purchase cannabis. This has made it difficult for cannabis companies to operate and navigate the regulatory environment.

Despite these challenges, Australia's cannabis market is expanding. The Australian Securities Exchange (ASX) lists cannabis stocks that focus on areas such as medical cannabis provision, medical research and investment holdings.

Keep reading...Show less
Melodiol Global Health

Melodiol Global Health Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×